A new review published in the journal Molecular Psychiatry on Jul. 7 examines why standard antidepressants frequently show limited effectiveness for depression in patients with Alzheimer’s disease and Parkinson’s disease. The review argues that future treatments should target damaged brain circuits and molecular pathways that are often missed by current medications.
Researchers compiled decades of literature focusing on the co-occurrence of depression with neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s, to explain these treatment challenges. The authors state that more than one in three patients with either condition also experience depression—42% among those with Alzheimer’s and 35% among those with Parkinson’s—which can worsen quality of life and accelerate cognitive decline.
The review highlights that while traditional antidepressants act on broad monoaminergic systems, they may not address the localized circuit disruptions unique to neurodegeneration. "Standard antidepressants target broad monoaminergic systems, but may fail to engage the highly localized, disease-specific circuit disruptions unique to neurodegeneration," the authors wrote. As a result, research is increasingly focused on alternatives involving molecular pathology, inflammatory markers, and advanced neuroimaging.
The narrative review synthesized clinical data from several databases including MEDLINE, Embase, Web of Science, and ClinicalTrials.gov. It prioritized human clinical studies as well as in vivo neuroimaging investigations such as positron emission tomography (PET). Findings indicate distinct mechanistic differences between depression related to Alzheimer’s versus Parkinson's: early glutamatergic stress is prominent in Alzheimer's while altered reward-processing circuits are implicated in Parkinson's-related depression.
Emerging therapies discussed include intravenous ketamine—which has shown rapid symptom reduction for major depressive disorder but has not yet been tested directly for Alzheimer’s or Parkinson's—and compounds like dextromethorphan-bupropion or prucalopride that remain exploratory for these populations. In contrast, some options such as minocycline have failed to demonstrate consistent benefits in larger trials despite initial promise.
The authors conclude that treating neurodegenerative depression requires moving beyond symptom-based prescribing toward biology-driven interventions tailored through biomarkers and imaging techniques. They emphasize a need for future clinical trials to use biological stratification methods, so treatments can be matched more precisely to individual neural pathologies.
